CEFTAZIDIME Drug Patent Profile
✉ Email this page to a colleague
When do Ceftazidime patents expire, and when can generic versions of Ceftazidime launch?
Ceftazidime is a drug marketed by Acs Dobfar, Aurobindo Pharma Ltd, Wockhardt, B Braun, and Baxter Hlthcare. and is included in six NDAs.
The generic ingredient in CEFTAZIDIME is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.
Summary for CEFTAZIDIME
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 67 |
Patent Applications: | 7,279 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFTAZIDIME at DailyMed |
Recent Clinical Trials for CEFTAZIDIME
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Qianfoshan Hospital | N/A |
Arrevus Inc. | Phase 2 |
King Faisal Specialist Hospital & Research Center | Phase 3 |
Pharmacology for CEFTAZIDIME
Drug Class | Cephalosporin Antibacterial |